Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 35

1.

Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.

Rothé F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, Fumagalli D, Michiels S, Stylianos D, Moerman C, Detiffe JP, Larsimont D, Awada A, Piccart M, Sotiriou C, Ignatiadis M.

Ann Oncol. 2014 Jul 25. pii: mdu288. [Epub ahead of print]

PMID:
25185240
[PubMed - as supplied by publisher]
2.

Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?

Sonnenblick A, Fumagalli D, Sotiriou C, Piccart M.

Cancer Treat Rev. 2014 Aug 12. pii: S0305-7372(14)00144-3. doi: 10.1016/j.ctrv.2014.07.005. [Epub ahead of print] Review.

PMID:
25151406
[PubMed - as supplied by publisher]
3.

Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives.

Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E, Viale G, Sotiriou C, Piccart M.

J Clin Oncol. 2014 Sep 1;32(25):2794-2803. Epub 2014 Jul 21. Review.

PMID:
25049332
[PubMed - as supplied by publisher]
4.

Modelling soil borne fungal pathogens of arable crops under climate change.

Manici LM, Bregaglio S, Fumagalli D, Donatelli M.

Int J Biometeorol. 2014 Mar 11. [Epub ahead of print]

PMID:
24615638
[PubMed - as supplied by publisher]
5.

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, Piccart MJ, Loibl S, Denkert C, Smyth MJ, Joensuu H, Sotiriou C.

Ann Oncol. 2014 Aug;25(8):1544-50. doi: 10.1093/annonc/mdu112. Epub 2014 Mar 7.

PMID:
24608200
[PubMed - in process]
6.

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

Pogue-Geile KL, Kim C, Jeong JH, Tanaka N, Bandos H, Gavin PG, Fumagalli D, Goldstein LC, Sneige N, Burandt E, Taniyama Y, Bohn OL, Lee A, Kim SI, Reilly ML, Remillard MY, Blackmon NL, Kim SR, Horne ZD, Rastogi P, Fehrenbacher L, Romond EH, Swain SM, Mamounas EP, Wickerham DL, Geyer CE Jr, Costantino JP, Wolmark N, Paik S.

J Natl Cancer Inst. 2013 Dec 4;105(23):1782-8. doi: 10.1093/jnci/djt321. Epub 2013 Nov 21.

PMID:
24262440
[PubMed - indexed for MEDLINE]
7.

Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.

Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Piccart MJ, Joensuu H, Sotiriou C.

J Natl Cancer Inst. 2013 Jul 3;105(13):960-7. doi: 10.1093/jnci/djt121. Epub 2013 Jun 5.

PMID:
23739063
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-silico analysis.

Azim HA Jr, Singhal S, Ignatiadis M, Desmedt C, Fumagalli D, Veys I, Larsimont D, Piccart M, Michiels S, Sotiriou C.

PLoS One. 2013 Apr 26;8(4):e62451. doi: 10.1371/journal.pone.0062451. Print 2013. Erratum in: PLoS One. 2013;8(12). doi:10.1371/annotation/3d5a5933-791f-4191-98f5-f559a872e404.

PMID:
23638089
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.

Gavin PG, Colangelo LH, Fumagalli D, Tanaka N, Remillard MY, Yothers G, Kim C, Taniyama Y, Kim SI, Choi HJ, Blackmon NL, Lipchik C, Petrelli NJ, O'Connell MJ, Wolmark N, Paik S, Pogue-Geile KL.

Clin Cancer Res. 2012 Dec 1;18(23):6531-41. doi: 10.1158/1078-0432.CCR-12-0605. Epub 2012 Oct 8.

PMID:
23045248
[PubMed - indexed for MEDLINE]
Free Article
10.

Genomic grade adds prognostic value in invasive lobular carcinoma.

Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Haussy S, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart M, Sotiriou C.

Ann Oncol. 2013 Feb;24(2):377-84. doi: 10.1093/annonc/mds280. Epub 2012 Oct 1.

PMID:
23028037
[PubMed - indexed for MEDLINE]
Free Article
11.

Molecular biology in breast cancer: should molecular classifiers be assessed by conventional tools or by gene expression arrays?

Fumagalli D, Andre F, Piccart-Gebhart MJ, Sotiriou C, Desmedt C.

Crit Rev Oncol Hematol. 2012 Dec;84 Suppl 1:e58-69. doi: 10.1016/j.critrevonc.2012.08.003. Epub 2012 Sep 7. Review.

PMID:
22964299
[PubMed - indexed for MEDLINE]
12.

Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?

Zardavas D, Fumagalli D, Loi S.

Curr Opin Oncol. 2012 Nov;24(6):623-34. doi: 10.1097/CCO.0b013e328358a2b5. Review.

PMID:
22960556
[PubMed - indexed for MEDLINE]
13.

A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints.

Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart M; BIG-NABCG collaboration.

Lancet Oncol. 2012 Jun;13(6):e240-8. doi: 10.1016/S1470-2045(11)70378-3.

PMID:
22652232
[PubMed - indexed for MEDLINE]
14.

Proteomic analysis in clear cell renal cell carcinoma: identification of differentially expressed protein by 2-D DIGE.

Raimondo F, Salemi C, Chinello C, Fumagalli D, Morosi L, Rocco F, Ferrero S, Perego R, Bianchi C, Sarto C, Pitto M, Brambilla P, Magni F.

Mol Biosyst. 2012 Apr;8(4):1040-51. doi: 10.1039/c2mb05390j. Epub 2012 Feb 8.

PMID:
22315040
[PubMed - indexed for MEDLINE]
15.

Gene profiling assay and application: the predictive role in primary therapy.

Fumagalli D, Desmedt C, Ignatiadis M, Loi S, Piccart M, Sotiriou C.

J Natl Cancer Inst Monogr. 2011;2011(43):124-7. doi: 10.1093/jncimonographs/lgr040.

PMID:
22043058
[PubMed - indexed for MEDLINE]
16.

Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.

Kim C, Tang G, Pogue-Geile KL, Costantino JP, Baehner FL, Baker J, Cronin MT, Watson D, Shak S, Bohn OL, Fumagalli D, Taniyama Y, Lee A, Reilly ML, Vogel VG, McCaskill-Stevens W, Ford LG, Geyer CE Jr, Wickerham DL, Wolmark N, Paik S.

J Clin Oncol. 2011 Nov 1;29(31):4160-7. doi: 10.1200/JCO.2010.32.9615. Epub 2011 Sep 26.

PMID:
21947828
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Unravelling the epigenomic dimension of breast cancers.

Dedeurwaerder S, Fumagalli D, Fuks F.

Curr Opin Oncol. 2011 Nov;23(6):559-65. doi: 10.1097/CCO.0b013e32834bd481. Review.

PMID:
21946247
[PubMed - indexed for MEDLINE]
18.

Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types.

Loi S, Symmans WF, Bartlett JM, Fumagalli D, Van't Veer L, Forbes JF, Bedard P, Denkert C, Zujewski J, Viale G, Pusztai L, Esserman LJ, Leyland-Jones BR.

Lancet Oncol. 2011 Nov;12(12):1162-8. doi: 10.1016/S1470-2045(11)70117-6.

PMID:
21684810
[PubMed - indexed for MEDLINE]
19.

Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection.

Criscitiello C, Fumagalli D, Saini KS, Loi S.

Onco Targets Ther. 2010 Dec 17;4:1-11. doi: 10.2147/OTT.S10155.

PMID:
21552410
[PubMed]
Free PMC Article
20.

CD44+ CD24-/low phenotype and resistance to trastuzumab in HER2-positive breast cancer cell lines.

Fumagalli D, Michiels S, Sotiriou C.

Pharmacogenomics. 2011 Jan;12(1):12-3. No abstract available.

PMID:
21213459
[PubMed]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk